LVM Capital Management Ltd. MI raised its holdings in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 0.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 61,606 shares of the medical research company’s stock after acquiring an additional 89 shares during the quarter. Amgen makes up about 2.0% of LVM Capital Management Ltd. MI’s portfolio, making the stock its 16th largest holding. LVM Capital Management Ltd. MI’s holdings in Amgen were worth $14,898,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Pacifica Partners Inc. increased its position in Amgen by 7.1% during the 1st quarter. Pacifica Partners Inc. now owns 601 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 40 shares during the period. Gryphon Financial Partners LLC increased its position in Amgen by 4.4% during the 4th quarter. Gryphon Financial Partners LLC now owns 1,040 shares of the medical research company’s stock valued at $234,000 after purchasing an additional 44 shares during the period. Formidable Asset Management LLC increased its position in Amgen by 1.9% during the 4th quarter. Formidable Asset Management LLC now owns 2,376 shares of the medical research company’s stock valued at $541,000 after purchasing an additional 45 shares during the period. Sierra Capital LLC grew its position in shares of Amgen by 7.1% in the 4th quarter. Sierra Capital LLC now owns 678 shares of the medical research company’s stock worth $153,000 after buying an additional 45 shares during the period. Finally, Samalin Investment Counsel LLC grew its position in shares of Amgen by 5.2% in the 4th quarter. Samalin Investment Counsel LLC now owns 932 shares of the medical research company’s stock worth $210,000 after buying an additional 46 shares during the period. Hedge funds and other institutional investors own 79.01% of the company’s stock.
AMGN has been the topic of a number of recent research reports. SVB Leerink initiated coverage on shares of Amgen in a research report on Monday, May 23rd. They issued a “market perform” rating and a $256.00 target price on the stock. Morgan Stanley reduced their target price on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 12th. Mizuho upped their price target on shares of Amgen from $202.00 to $208.00 in a research note on Tuesday, May 10th. Oppenheimer upped their price target on shares of Amgen from $285.00 to $290.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 1st. Finally, StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 16th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $242.57.
Shares of NASDAQ:AMGN opened at $240.14 on Thursday. The firm’s 50 day moving average price is $244.62 and its 200-day moving average price is $234.69. Amgen Inc. has a twelve month low of $198.64 and a twelve month high of $258.45. The company has a quick ratio of 1.09, a current ratio of 1.44 and a debt-to-equity ratio of 39.31. The stock has a market capitalization of $128.28 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57.
Amgen (NASDAQ:AMGN – Get Rating) last issued its quarterly earnings data on Wednesday, April 27th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.22 by $0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The firm had revenue of $6.24 billion for the quarter, compared to analysts’ expectations of $6.09 billion. During the same quarter in the prior year, the business earned $3.70 EPS. Analysts expect that Amgen Inc. will post 17.44 earnings per share for the current fiscal year.
Amgen Company Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.